Deal Values in Pharmaceutical & Healthcare Industry Increased in 2015

Monday 9 May 2016, Amsterdam

Market Research Report Press Release Deal Values in Pharmaceutical & Healthcare Industry Increased in 2015
“Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in 2015. The report discloses detailed comparative data on the number of deals and their value in the past five years, categorized into deal types, segments, and geographies. The report provides information on the top private equity, venture capital and advisory firms in the pharmaceutical and healthcare industry.

Deal Values Of M&A’s Increased In 2015
Mergers and acquisitions (M&As), including asset purchases, registered a decrease in the number of deals and an increase in deal values in 2015 with 960 deals worth USD432.9 billion, as compared to 1,141 deals worth USD411.1 billion in 2014.
Oncology therapeutics market accounted for the highest number of M&A deals, followed by central nervous system therapeutics market during 2015. Oncology therapeutics market registered 138 deals worth USD267.2 billion and central nervous system therapeutics market reported 134 deals worth USD269.2 billion during 2015.

Deal Values of Licensing Agreements Increased In 2015
Licensing agreements recorded an increase in deal values in 2015. The segment recorded USD42 billion in 2015, as compared to USD35.1 billion in 2014. However, the number of deals decreased marginally to 605 deals in 2015 from 606 deals in 2014.
Oncology therapeutics market dominated the industry by reporting 184 licensing deals worth USD18.2 billion during 2015. The central nervous system therapeutics market stood second with 84 licensing deals worth USD3.6 billion during the same period.
Licensing agreements recorded an increase in upfront payments and milestone payments during 2015. The segment reported USD2.4 billion in upfront payments and USD25.4 billion in milestone payments in 2015, as compared to USD2.2 billion and USD20.2 billion, respectively, in 2014.
In licensing by phase, products in Preclinical recorded 100 deals, accounting for 31% of the total deals in 2015. In second place, products in Phase II accounted for 20% of the deals.

Partnership Deals Increased In 2015
Partnerships deals recorded an increase in the number of deals and deal values in 2015. The segment reported 1,022 deals worth USD25.1 billion in 2015, as compared to 739 deals worth USD18.5 billion in 2014.
The oncology therapeutics market stood ahead of all other therapeutics markets with 317 partnerships worth USD11.3 billion in 2015. The central nervous system therapeutics market followed with 121 deals worth USD2.5 during the same period.

Capital Raising Through Issuance Of Equity Reported An Increase In 2015
Equity offerings reported an increase in the number of deals in 2015. The segment registered 999 deals in 2015, as compared to 822 deals in 2014. Deal values also increased to USD82.2 billion in 2015 from USD42.4 billion in 2014.
The IPO market recorded same number of deals and a decline deal values with 139 deals worth USD12.7 billion in 2015, as compared to 139 deals worth USD15.9 billion in 2014.
Secondary offerings reported 346 deals in 2015, as compared to 264 deals in 2014, reflecting a decrease of 31%. Deal values increased to USD51.2 billion in 2015 from USD17.2 billion in 2014. Besides, PIPE deals reported an increase in deal values in 2015. The deal values increased to USD18.3 billion in 2015 from USD9.4 billion in 2014. The number of deals also increased to 514 in 2015 from 419 in 2014.

Venture Capital Investments Increased In 2015
The pharmaceutical and healthcare industry recorded a decrease the number of venture capital (VC) deals and an increase in their values in 2015. The market reported 732 deals worth USD13 billion in 2015, as compared to 1,111 deals worth USD10.1 billion in 2014.
New Enterprise Associates, Inc. topped the list of venture financing firms with participating in 22 transactions worth USD877.1m in 2015.

North America Reported An Increase In Deal Values In 2015
North America recorded an increase in the number of deals and deal values with 2,946 deals worth USD553.2 billion in 2015, as compared to 3,198 deals worth USD435.3 billion in 2014.
Europe recorded an increase in the number of deals with 1,510 deals in 2015, as compared to 1,393 deals in 2014. However, deal values increased from USD273.6 billion in 2014 to USD200.2 billion in 2015.
The Asia Pacific region recorded an increase in the number of deals and a decrease in deal values with 1,034 deals worth USD88.8 billion in 2015, as compared to 920 deals worth USD95.4 billion in 2014.
Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals

Publish date : April 2016
Report code : ASDR-270802
Pages : 173

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News